Trial
NCT04240704
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non-Hodgkins Lymphoma
Intervention
JBH492
Why stopped
Business, strategic, and development considerations and not due to any safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-10